[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"quadriplegiatetraplegia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:quadriplegiatetraplegia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,82,120,147,184,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100577433","development-and-validation-of-a-new-questionnaire-for-caregivers-to-assess-hip-pain-in-quadriplegic-pediatric-patients-non-ambulatory-hip-pain-questionnaire-100577433",false,"NCT06798233","Development and Validation of a New Questionnaire for Caregivers to Assess Hip Pain in Quadriplegic Pediatric Patients: Non-Ambulatory Hip Pain Questionnaire","NAHPq","Inclusion Criteria:\n\n* GMFCS IV-V\n* CFCS III-V\n* subscription of consent\n\nExclusion Criteria:\n\n* care givers not speaking Italian or English","ALL","1 Year","20 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is twofold:\n\n1. to develop a questionnaire for care givers to assess hip pain in quadriplegic pediatric patients who are not able to communicate it independently\n2. to validate this questionnaire in a cohort of 100 pediatric patients with quadriplegia\n\nResearchers will :\n\n1. involve 10 experts (8 multiprofessional clinicians and 2 parents) in a Delphi approach to develop the questionnaire\n2. assess construct validity and reliability of the questionnaire submitting it to 100 care givers of pediatric patients with quadriplegia, and comparing results with the Revised Face Legs Activity Cry and Consolability (r-FLACC) Scale assessed by the physiatrist during the visit\n\nParticipants will:\n\n1. as experts, firstly answer open questions on this topic, secondly evaluate each item of the new questionnaire by means of a 5-point Liekert scale\n2. as caregivers of pediatric patients with quadriplegia, fill out the questionnaire within 2 weeks after the visit",[27],"Quadriplegia\u002FTetraplegia",[29,30,31,32,33],"hip pain","pain measurements","children","adolescents","cerebral palsy","RECRUITING","2026-05-04",{"date":37,"type":38},"2026-05-07","ACTUAL",{"date":40,"type":38},"2024-07-17",{"date":42,"type":21},"2026-12",{"name":44,"class":45},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100626647","home-based-digital-rehabilitation-program-optimized-with-transcutaneous-spinal-cord-stimulation-for-upper-limb-functional-enhancement-in-tetraplegia-hope-a-safety-efficacy-and-feasibility-study-100626647","NCT07438353","Home-Based Digital Rehabilitation Program Optimized With Transcutaneous Spinal Cord Stimulation for Upper Limb Functional Enhancement in Tetraplegia (HOPE): A Safety, Efficacy, and Feasibility Study","HOPE","Inclusion Criteria:\n\nParticipant\n\n* Age 21 -75 years;\n* Non-progressive cervical SCI\u002Fspinal cord dysfunction (traumatic or non-traumatic);\n* Duration of SCI\u002Fspinal cord dysfunction more than or equal to 12 months;\n* ASIA Impairment scale (AIS B, C, or D) with impaired upper limb function;\n* At least one hand capable of grasp and pinch, with or without assistive modification;\n* International Standards for Neurological Classification of Spinal Cord Injury-Upper Extremity Measurement Scale (ISNCSCI-UEMS) more than or equal to 20;\n* Able to maintain an upright sitting position for at least 30 minutes;\n* No contraindication for tSCS (e.g., no pacemakers or other implantable stimulators);\n* Motivated and able to engage in a daily home-based rehabilitation program;\n* Availability of a dedicated care-giver to set up digital home-based therapy program\n\nCaregiver\n\n* Age 21 -75 years;\n* As identified by the patient as the caregiver;\n* Willing to participate in the study\n\nExclusion Criteria:\n\nParticipant\n\n* Significant or unstable medical co-morbidities including uncontrolled cardiopulmonary disease, severe cognitive impairment, severe dysautonomia, as determined by the investigator;\n* Pregnancy;\n* History of other neurologic conditions affecting upper limb function, such as stroke, multiple sclerosis, or traumatic brain injury;\n* Known history of peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc);\n* Ongoing treatment for cancer;\n* Skin conditions or active cancerous lesion that limit the application of tSCS electrodes\n* Known contraindication for tSCS (pacemakers or other implantable stimulators);\n* Prior exposure to tSCS treatment;\n* Inability to provide informed consent.\n\nCaregiver:\n\n• Inability to provide informed consent.","21 Years","75 Years",{"count":57,"type":21},9,[24],"Individuals with chronic cervical spinal cord injury (SCI) and tetraplegia commonly experience persistent impairment in upper limb function, leading to reduced independence and quality of life. Transcutaneous spinal cord stimulation (tSCS) is a non-invasive neuromodulation technique that has demonstrated potential to improve upper limb strength and function when combined with rehabilitation. However, access to tSCS is limited in Singapore due to cost, regulatory barriers, and the need for frequent outpatient therapy.\n\nThis study evaluates the safety, efficacy, and feasibility of a home-based digital rehabilitation program incorporating tSCS delivered using a commercially available neuromuscular electrical stimulation (NMES) device. Using a prospective, open-label single-case experimental design with multiple baselines across participants, individuals with chronic, non-progressive cervical SCI will receive daily home-based tSCS combined with an mobile application-guided upper limb exercise program. Upper limb function, quality of life, feasibility, and safety outcomes will be assessed longitudinally over a 22-week study period.",[61,27],"Spinal Cord Injury",[63,64,65,66,67,68,69,61],"Transcutaneous spinal cord stimulation","Tetraplegia","Telerehabilitation","Rehabilitation Technology","Digital Rehabilitation","Home-Based Rehabilitation","Neuromodulation","NOT_YET_RECRUITING","2026-02-22",{"date":73,"type":38},"2026-02-27",{"date":75,"type":21},"2026-04",{"date":77,"type":21},"2027-12",{"name":79,"class":80},"Singapore General Hospital","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":55,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":101,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":46},"100549109","precise-robotically-implanted-brain-computer-interface-100549109","NCT06429735","Precise Robotically IMplanted Brain-Computer InterfacE","PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices","PRIME","Inclusion Criteria:\n\n* Severe quadriplegia (tetraplegia) due to spinal cord injury or amyotrophic lateral sclerosis (ALS) for at least 1 year without improvement, where quadriplegia is defined as having very limited or no hand, wrist, and arm movement and all levels below\n* Life expectancy ≥ 12 months.\n* Ability to communicate in English\n* Presence of a stable caregiver\n\nExclusion Criteria\n\n* Moderate to high risk for serious perioperative adverse events\n* Active implanted devices\n* Morbid obesity (Body Mass Index \\> 40)\n* History of poorly controlled seizures or epilepsy\n* History of poorly controlled diabetes\n* Requires magnetic resonance imaging (MRI) for any ongoing medical conditions\n* Acquired or hereditary immunosuppression\n* Use of smoking tobacco or other tobacco products\n* Psychiatric or psychological disorder\n* Brain MRI demonstrating hemorrhage, tumor, distorted or adverse anatomy.\n* Any condition which, in the opinion of the Investigator, would compromise your ability to safely participate in the study or undergo the implantation procedure","22 Years",{"count":92,"type":21},15,[24],"The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode threads that are implanted in the brain by the R1 Robot, a robotic electrode thread inserter.",[96,97,98,99,27,100],"Tetraplegia\u002FTetraparesis","Quadriplegia","Cervical Spinal Cord Injury","Amyotrophic Lateral Sclerosis","Tetraplegic; Paralysis",[102,103,104,105,106,107,108,109],"spinal cord injury","SCI","BCI","brain computer interface","ALS","quadriplegia","tetraplegic","paralysis","2026-01-07",{"date":112,"type":38},"2026-01-09",{"date":114,"type":38},"2024-01-09",{"date":116,"type":21},"2031-01",{"name":118,"class":119},"Neuralink Corp","INDUSTRY",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":55,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":81},"100610182","voice-an-early-feasibility-study-of-a-precise-robotically-implanted-brain-computer-interface-for-communication-restoration-100610182","NCT07224256","VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration","Inclusion Criteria:\n\nAdults with diagnosis of ALS, PLS, stroke, or Spinal Cord Injury who have severe speech impairment and impaired upper limb function.\n\n* Life expectancy ≥ 12 months.\n* Ability to communicate in English\n* Presence of a stable caregiver\n\nExclusion Criteria\n\n* Moderate to high risk for serious perioperative adverse events\n* Morbid obesity (Body Mass Index \\> 40)\n* History of poorly controlled seizures or epilepsy\n* History of poorly controlled diabetes\n* Requires magnetic resonance imaging (MRI) for any ongoing medical conditions\n* Acquired or hereditary immunosuppression\n* Psychiatric or psychological disorder\n* Brain MRI demonstrating hemorrhage, tumor, distorted or adverse anatomy.\n* Any condition which, in the opinion of the Investigator, would compromise your ability to safely participate in the study or undergo the implantation procedure",{"count":127,"type":21},6,[24],"The VOICE Study is an early feasibility study to evaluate the initial clinical safety and efficacy of the N1 and R1 Systems device design concept in providing an ability to communicate. The Neuralink N1 Implant is intended to provide the ability to communicate to individuals with severe and irreversible speech production impairment. It is indicated for adults with neurological conditions of the central speech pathways who have impaired upper limb function. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode threads that are implanted in the brain by the R1 Robot, a robotic electrode thread inserter.",[96,97,98,99,27,100,131],"Stroke",[133,102,103,106,105,104,134,135,136,137,138],"stroke","PLS","voice","speech","dysarthria","neuralink","2025-10-31",{"date":141,"type":38},"2025-11-04",{"date":143,"type":38},"2025-10-03",{"date":145,"type":21},"2031-10",{"name":118,"class":119},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":154,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":163,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":46},"100602719","gb-prime-an-early-feasibility-study-of-a-precise-robotically-implanted-brain-computer-interface-for-the-control-of-external-devices-100602719","NCT07127172","GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices","GB-PRIME","Inclusion Criteria:\n\n* (a) A diagnosis of a spinal cord injury, brain stem stroke, or other neurological condition causing the participant to be non-ambulant and with bilateral upper limb motor impairment with no expectation of recovery that significantly or completely impairs the participant's ability to manually control a computer, smartphone or tablet with their hands.\n\nOR (b) A diagnosis of Amyotrophic Lateral Sclerosis (ALS) or other progressive neurological condition where the natural history of the disease is well understood and where there is tetraparesis and the expectation in the view of the participants treating neurologist that the disease will progress such that the participant will meet 1a within 1 year of recruitment.\n\n* Life expectancy ≥ 12 months.\n* Ability to communicate in English\n* Presence of a stable caregiver\n\nExclusion Criteria:\n\n* Moderate to high risk for serious perioperative adverse events\n* Active implanted devices\n* Morbid obesity (Body Mass Index \\> 40)\n* History of poorly controlled seizures or epilepsy\n* History of poorly controlled diabetes\n* Requires magnetic resonance imaging (MRI) for any ongoing medical conditions\n* Acquired or hereditary immunosuppression\n* Use of smoking tobacco or other tobacco products\n* Psychiatric or psychological disorder\n* Brain MRI demonstrating hemorrhage, tumor, distorted or adverse anatomy.\n* Any condition which, in the opinion of the Investigator, would compromise your ability to safely participate in the study or undergo the implantation procedure","18 Years",{"count":5,"type":21},[24],"The GB-PRIME Study is an early feasibility study designed to assess the clinical safety and functionality of the Neuralink N1 Implant and R1 Robot. This study involves participants who have tetraparesis, tetraplegia, or a diagnosis that may lead to these conditions.\n\nThe N1 Implant is a wireless, rechargeable device mounted on the skull, connected to electrode threads that are inserted into the brain by the R1 Robot, which is a robotic device specifically designed for this procedure.",[96,97,27,98,159,160,61,161,162],"Amyotrophic Lateral Sclerosis (ALS)","Spinal Cord Injury (Quadraplegia)","Motor Neuron Disease","Brain Stem Stroke",[105,164,165,166,167,168,107,106,102,169,170,171,172,173,174,103,109,175],"Neuralink N1 Implant","Neuralink","Robot","tetraparesis","tetraplegia","Amyotrophic lateral sclerosis","chip","brain chip","External device control","Wireless implant","Neuroprosthetics","motor neuron disease","2025-08-11",{"date":178,"type":38},"2025-08-17",{"date":180,"type":38},"2025-07-31",{"date":182,"type":21},"2031-02",{"name":118,"class":119},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":154,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":81},"100592374","uae-prime-a-feasibility-study-of-a-precise-robotically-implanted-brain-computer-interface-for-the-control-of-external-devices-100592374","NCT06992596","UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices","UAE-PRIME","Inclusion Criteria:\n\n* (a) A diagnosis of a spinal cord injury (\\>12 months), stroke (\\>12 months), or other neurological condition causing the participant to experience bilateral upper limb motor impairment, with no expectation of recovery.\n\nOR (b) A diagnosis of Amyotrophic Lateral Sclerosis (ALS) or other progressive neurological condition where the natural history of the disease is well understood and where there is tetraparesis and the expectation, in the view of the participant's treating neurologist, that the disease will progress such that the participant will meet criteria 1a within 1 year of recruitment.\n\n* Life expectancy ≥ 12 months.\n* Ability to communicate verbally or with the use of a computer or communication aid, and working proficiency in English.\n* Presence of a stable caregiver\n\nExclusion Criteria:\n\n* Moderate to high risk for serious perioperative adverse events\n* Morbid obesity (Body Mass Index \\> 40)\n* History of poorly controlled seizures or epilepsy\n* History of poorly controlled diabetes\n* Requires magnetic resonance imaging (MRI) for any ongoing medical conditions\n* Acquired or hereditary immunosuppression\n* Smoking tobacco or use of other tobacco products \\> once per month within the last year.\n* Psychiatric or psychological disorder\n* Pre-existing damage to the cortical region of interest (as determined by MRI)\n* Any condition which, in the opinion of the Investigator, would compromise your ability to safely participate in the study or undergo the implantation procedure",{"count":192,"type":21},10,[24],"The UAE-PRIME Study is a feasibility study designed to assess the initial clinical safety and functionality of the Neuralink N1 Implant and R1 Robot. This study involves participants who have tetraparesis, tetraplegia, or a diagnosis that may lead to these conditions.\n\nThe N1 Implant is a wireless, rechargeable device mounted on the skull, connected to electrode threads that are inserted into the brain by the R1 Robot, which is a robotic device specifically designed for this procedure.",[96,97,27,98,159,160,61,161,162],[105,164,165,166,167,168,107,106,102,169,170,171,172,173,174,103,109,175],"2025-06-03",{"date":199,"type":38},"2025-06-05",{"date":201,"type":38},"2025-05-09",{"date":203,"type":21},"2027-11",{"name":118,"class":119},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":213,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":81},"100569904","can-prime-precise-robotically-implanted-brain-computer-interface-for-the-control-of-external-devices-100569904","NCT06700304","CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices","CAN-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices","CAN-PRIME","Inclusion Criteria:\n\n* Severe quadriplegia (tetraplegia) due to spinal cord injury or amyotrophic lateral sclerosis (ALS) for at least 1 year without improvement, where quadriplegia is defined as having very limited or no hand, wrist, and arm movement and all levels below\n* Life expectancy ≥ 12 months.\n* Ability to communicate in English\n* Presence of a stable caregiver\n\nExclusion Criteria:\n\n* Moderate to high risk for serious perioperative adverse events\n* Active implanted devices\n* Morbid obesity (Body Mass Index \\> 40)\n* History of poorly controlled seizures or epilepsy\n* History of poorly controlled diabetes\n* Requires magnetic resonance imaging (MRI) for any ongoing medical conditions\n* Acquired or hereditary immunosuppression\n* Use of smoking tobacco or other tobacco products\n* Psychiatric or psychological disorder\n* Brain MRI demonstrating hemorrhage, tumor, distorted or adverse anatomy.\n* Any condition which, in the opinion of the Investigator, would compromise your ability to safely participate in the study or undergo the implantation procedure","19 Years",{"count":127,"type":21},[24],"The CAN-PRIME Study is to test the safety and functionality of Neuralink's N1 Implant and R1 Robot in people who have difficulty moving their arms and legs (tetraparesis or tetraplegia). The N1 Implant is a small, wireless device placed in the skull. It connects to tiny threads inserted into the brain by the R1 Robot, which is a machine designed to carefully place these threads. This study will help researchers learn how well the implant and robot work and if they are safe for use.",[96,97,27,98,159,160,61],[105,164,165,166,167,168,107,106,102,169,170,171,172,173,174,103,109],"2025-05-27",{"date":221,"type":38},"2025-05-31",{"date":223,"type":38},"2024-11-20",{"date":225,"type":21},"2030-11-30",{"name":118,"class":119}]